Evidence map›Paper›PMID 35158994›Full record

ArticleCancers2022

Glioblastoma Cells Counteract PARP Inhibition through Pro-Survival Induction of Lipid Droplets Synthesis and Utilization.

Jara Majuelos-Melguizo, José Manuel Rodríguez-Vargas, Nuria Martínez-López, Daniel Delgado-Bellido, Ángel García-Díaz, Víctor J Yuste, Marina García-Macía, Laura M López, Rajat Singh, F J Oliver

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Hirudin inhibits glioma growth through mTOR-regulated autophagy.Journal of cellular and molecular medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jara Majuelos-MelguizoDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.ORCID 0000-0003-1841-1345
José Manuel Rodríguez-VargasDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.ORCID 0000-0001-8141-1693
Nuria Martínez-LópezInstitute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-8220-6015
Daniel Delgado-BellidoDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.ORCID 0000-0002-9588-4747
Ángel García-DíazDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.
Víctor J YusteCell Death, Senescence and Survival Group, Department of Biochemistry and Molecular Biology and Institute of Neurosciences, Faculty of Medicine, Autonomous University of Barcelona, CIBERNED, 08193 Barcelona, Spain.ORCID 0000-0001-5322-9261
Marina García-MacíaInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-3908-9060
Laura M LópezDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.
Rajat SinghDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
F J OliverDepartment of Immunology and Cell Biology, Institute of Parasitology and Biomedicine "López-Neyra", IPBLN, CSIC, CIBERONC, 18016 Granada, Spain.ORCID 0000-0001-8468-1998
Instituto de Parasitología y Biomedicina "López - Neyra" · ESNewcastle University · GBAlbert Einstein College of Medicine · USInstituto de Investigaciones Biomédicas Sols-Morreale · ESUniversitat Autònoma de Barcelona · ES

Funding

CIBER Cancer ISCIII CB16/12/00421Junta de Andalucía, Project of Excellence P10-CTS-0662RTICC RD12/0036/0026Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new class of anti-neoplastic drugs. In the current study, we have characterized the mechanism by which glioblastoma cells evade the effect of PARPi as anti-tumor agents. We have found that suppression of PARP activity exerts an anti-stemness effect and has a dual impact on autophagy, inducing its activation in the first 24 h (together with down-regulation of the pro-survival mTOR pathway) and preventing autophagosomes fusion to lysosomes at later time-points, in primary glioma cells. In parallel, PARPi triggered the synthesis of lipid droplets (LDs) through ACC-dependent activation of de novo fatty acids (FA) synthesis. Notably, inhibiting β-oxidation and blocking FA utilization, increased PARPi-induced glioma cell death while treatment with oleic acid (OA) prevented the anti-glioma effect of PARPi. Moreover, LDs fuel glioma cells by inducing pro-survival lipid consumption as confirmed by quantitation of oxygen consumption rates using Seahorse respirometry in presence or absence of OA. In summary, we uncover a novel mechanism by which glioblastoma escapes to anti-tumor agents through metabolic reprogramming, inducing the synthesis and utilization of LDs as a pro-survival strategy in response to PARP inhibition.

Indexed as

Acyl-coA-carboxylaseglioblastoma stem cellslipid dropletslipophagymetabolic adaptationPARP inhibitors

Identifiers

PMID35158994
PMCPMC8833394
OpenAlexW4210364163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.